Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report

Neurol Sci. 2021 Sep;42(9):3933-3935. doi: 10.1007/s10072-021-05379-9. Epub 2021 Jun 25.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Humans
  • Immunologic Factors
  • Neutropenia* / chemically induced
  • Rituximab

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Rituximab
  • ocrelizumab